Changing trends from inguinal radical orchiectomy to testis-sparing surgery in pediatric testicular tumors by Özlem Balcı, Aslı Nur Abay, Şule Yeşil, İbrahim Karaman, İsmet Faruk Özgüner, Burçak Kurucu, Derya Erdoğan, Gürses Şahin, Ayşe Karaman

“…Testicular biopsy was performed in 9 cases for testicular involvement of Leukemia and Lymphoma. No recurrence was detected with a median follow-up of 6.5 years. …”
Get full text

Changes in the Expression of Mitochondrial Morphology-Related Genes during the Differentiation of Murine Embryonic Stem Cells by Jeong Eon Lee, Bong Jong Seo, Min Ji Han, Yean Ju Hong, Kwonho Hong, Hyuk Song, Jeong Woong Lee, Jeong Tae Do

“…Pluripotent ESCs maintain stemness in the presence of leukemia inhibitory factor (LIF) via the JAK-STAT3 pathway but lose pluripotency and differentiate in response to the withdrawal of LIF. …”
Get full text

Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity by Mariana P. Miranda-Hernández, Carlos A. López-Morales, Nancy D. Ramírez-Ibáñez, Nelly Piña-Lara, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, Emilio Medina-Rivero

“…Rituximab is a chimeric monoclonal antibody employed for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. …”
Get full text

A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC₅₀ Inhibition Values of FLT3 Tyrosine Kinase by Jackson J. Alcázar, Ignacio Sánchez, Cristian Merino, Bruno Monasterio, Gaspar Sajuria, Diego Miranda, Felipe Díaz, Paola R. Campodónico

“…<b>Background/Objectives:</b> Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly in cases driven by mutations in the FLT3 tyrosine kinase. …”
Get full text

Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks by Elena Díaz-Santiago, Aurelio A. Moya-García, Jesús Pérez-García, Raquel Yahyaoui, Raquel Yahyaoui, Christine Orengo, Florencio Pazos, James R. Perkins, James R. Perkins, James R. Perkins, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea

“…The top results include phenotype-drug associations that represent intended effects, particularly for cancers such as chronic myelogenous leukemia, which was linked with nilotinib. They also include adverse side effects, such as blurred vision being linked with tetracaine.DiscussionThis work represents an important advance in our understanding of how drugs cause intended and adverse side effects through their action on disease causing genes and has potential applications for drug development and repositioning.…”
Get full text

Synthesis and Characterization of New Palladium(II) Thiosemicarbazone Complexes and Their Cytotoxic Activity against Various Human Tumor Cell Lines by Wilfredo Hernández, Juan Paz, Fernando Carrasco, Abraham Vaisberg, Evgenia Spodine, Jorge Manzur, Lothar Hennig, Joachim Sieler, Steffen Blaurock, Lothar Beyer

“…Among all the studied palladium(II) complexes, the [Pd(TSC3)2] (8) complex exhibited high antitumor activity on the DU145 prostate carcinoma and K562 chronic myelogenous leukemia cells, with low values of the inhibitory concentration (0.01 and 0.02 μM, resp.).…”
Get full text

Assessment of physiological status of felids as indicator of their welfare in the wild by Ekaterina V. Pavlova, Evgeny A. Ivanov, Vadim E. Kiriluk, Vyacheslav V. Rozhnov

“…Pallas cats had the lowest occurrence of positive reactions to 4 pathogens: Toxoplasma gondii (12.5%), Mycoplasma sp. (12.5%), influenza A (7.1%), and feline leukemia virus (8.3%). Leopards had the highest N:L and occurrence of seropositive reactions only to 2 infections: T. gondii (16.6%) and Candida sp. (100%). …”
Get full text

Case report: Toxic epidermal necrolysis as a unique presentation of acute graft versus host disease in a pediatric patient by Elizabeth Marlowe, Rachel Palmer, April L. Rahrig, Devin Dinora, Jessica Harrison, Jodi Skiles, Mahvish Q. Rahim

“…Management and outcomes of pediatric patients with this overlapping, severe presentation have rarely been described.Case presentationThis report describes an 11-year-old boy with refractory T-cell acute lymphoblastic leukemia who received peripheral blood SCT from a matched unrelated donor. …”
Get full text

LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells by Jianxia Xu, Jingxin Zhang, Chengsi Zhang, Huali Hu, Siqi Wang, Fahua Deng, Wu Zhou, Yuancheng Liu, Chenlong Hu, Hai Huang, Sixi Wei

“…Methods ANRIL and CDKN2A expression levels were quantified using RT-qPCR in peripheral blood samples from acute myeloid leukemia (AML) patients. CDKN2A knockdown efficiency was validated via RT-qPCR, and cell cycle distribution was analyzed using flow cytometry. …”
Get full text

MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS by Chunlai Yin, Xue Yan, Jinyi Ren, Cheng Zhang, Jiaqing Liu, Zilong Wang, Jing Liu, Weiping Li, Xia Li

“…Abstract Background Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSCs), characterized by ineffective hematopoiesis and a high risk of progression to acute myeloid leukemia. Elucidating the mechanism underlying the dysfunction of MDS-HSCs is crucial for exploring the pathogenesis of the syndrome. …”
Get full text

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses by Alice Bergamini, Barbara Camisa, Attilio Bondanza, Fabio Ciceri, Chiara Bonini, Monica Casucci, Beatrice Greco, Camilla Bove, Silvia Arcangeli, Laura Falcone, Rita El Khoury, Anna De Lucia

“…To this aim, we took advantage of immunodeficient mice reconstituted with a human immune system (HuSGM3) and engrafted with the B-cell acute lymphoblastic leukemia cell line NALM-6, a model that allows to thoroughly study efficacy and toxicity profiles of CD19 CAR-T cell products.Results CD4 CAR-T cells showed superior proliferation and activation potential, which translated into stronger stimulation of myeloid cells, the main triggers of adverse events. …”
Get full text

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma... by A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy, R. LeBlanc, K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul, D. Reece

Get full text

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database by Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo

“…Abstract Background With the increased use of isocitrate dehydrogenase (IDH) inhibitors in acute myeloid leukemia (AML) and cholangiocarcinoma, the toxicity of these drugs is a growing concern. …”
Get full text

A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020–2021) by José-Manuel Ramos-Rincón, José-Manuel Ramos-Rincón, José Sánchez-Paya, Pilar González-De-La-Aleja, Juan-Carlos Rodríguez-Díaz, Juan-Carlos Rodríguez-Díaz, Esperanza Merino, Esperanza Merino

“…Risk factors for IHM remained consistent, with leukemia, neoplasm, and lymphoma posing the highest risks, while female sex (AOR: 0.75, 95% CI: 0.74–0.77, p &lt; 0.001) and dyslipidemia (AOR: 0.85, 95% CI: 0.32–0.86, p &lt; 0.001) were protective factors.ConclusionDuring the vaccination period, the risk of in-hospital mortality (IHM) was 29% lower than in the prevaccination period, after adjusting for sex, age, and comorbidities. …”
Get full text

Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality by Marianna Zahurak, Ravi Varadhan, Ilias Christodoulou, Ruyan Rahnama, Jun Choe, Huilin Yang, Monika Kizerwetter, Christian Guaraca, Natalie Jordan Holl, Stamatia C Vorri, Megan Zinsky, Danielle G Jones, Nikol Garcia Espinoza, Yun-Huai Kuo, Jamie B. Spangler, Challice L. Bonifant

“…Background Natural Killer (NK) cells have intrinsic anticancer activity that can be redirected toward acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) engineering. …”
Get full text

Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives by Ekaterina M. Zhidkova, Evgeniya S. Oleynik, Ekaterina A. Mikhina, Daria V. Stepanycheva, Diana D. Grigoreva, Lyubov E. Grebenkina, Kirill V. Gordeev, Ekaterina D. Savina, Andrey V. Matveev, Marianna G. Yakubovskaya, Ekaterina A. Lesovaya

“…We evaluated <i>in vitro</i> anti-cancer effects in leukemia K562 and lymphoma Granta cells using the MTT assay and studied their potential affinity for the glucocorticoid receptor (GR) <i>in silico</i> using the molecular docking approach. …”
Get full text

Therapeutic applications of artemisinin in ophthalmic diseases by Hao Sun, Ping Zhao, Lianghui Zhao, Zhizhong Zhao, Haoyu Chen, Cong Ren, Bin Guo

“…It is known for its curative effects in the treatment of pulmonary hypertension, leukemia, diabetes, malaria, and other diseases, owing to its abundant biological activity. …”
Get full text

Spontaneous high clonal expansion of Wilms’ tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms’ tumor gene 1-expressing solid tumor by Soyoko Morimoto, Yukie Tanaka, Jun Nakata, Fumihiro Fujiki, Kana Hasegawa, Hiroko Nakajima, Sumiyuki Nishida, Akihiro Tsuboi, Naoki Hosen, Naoki Kagawa, Motohiko Maruno, Akira Myoui, Takayuki Enomoto, Shuichi Izumoto, Mitsugu Sekimoto, Naoya Hashimoto, Toshiki Yoshimine, Atsushi Kumanogoh, Yusuke Oji, Yoshihiro Oka, Haruo Sugiyama

“…Abstract Wilms’ tumor protein 1 (WT1)-targeted immunotherapy has been used in patients with leukemia and solid tumors. However, the spontaneous WT1-specific immune response before WT1 peptide vaccination in patients with WT1-expressing tumors (PTs) remains unclear. …”
Get full text

The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2 by Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N Ward, Ian R Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles Boone, Chad L Myers, Yin Shen, Vijay Ramani, Brenda J Andrews, David P Toczyski

“…Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.…”
Get full text

Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study by Axel Benner, Peter Dreger, Grzegorz W Basak, Christian Koenecke, Olaf Penack, Christophe Peczynski, Lucia López Corral, Ivan Moiseev, Hélène Schoemans, Zinaida Peric, Thomas Luft, Simona Sica, Mutlu Arat, Maija Itäla-Remes, Nicolaas P M Schaap, Michal Karas, Ludek Raida, Thomas Schroeder, Elisabetta Metafuni, Tulay Ozcelik, Brenda M Sandmaier, Lambros Kordelas

“…For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network.Results Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. …”
Get full text